Blood Advances, a Journal of the American Society of Hematology, provides an open international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology and related sciences. Music for Blood Advances Talks is preformed by the Art Topilow Trio
…
continue reading
Big data are used in the pursuit of precision medicine in the general population. Applying these tools to patients with sickle cell disease (SCD) is essential for ensuring that they receive the most appropriate customized therapy for their disease. For these tools to be applied, there must be a large number of willing, fully phenotyped participants…
…
continue reading
1
Investigational curative gene therapy approaches to sickle cell disease
12:58
12:58
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
12:58
Sickle cell disease (SCD) is an inherited blood condition resulting from abnormal hemoglobin production. It is one of the most common genetic diseases in the world. The clinical manifestations are variable and range from recurrent acute and debilitating painful crises to life-threatening pulmonary, cardiovascular, renal, and neurologic complication…
…
continue reading
1
Why is AAV FVIII gene therapy not approved by the US Food and Drug Administration yet?
31:22
31:22
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
31:22
The prospect of a clinical strategy using an adeno-associated virus (AAV) vector for expression of therapeutic levels of factor VIII (FVIII) has been highly desirable. This was initially anticipated by promising data from clinical studies on AAV5-FVIII in men with severe hemophilia A. However, long-term follow-up showed a unique efficacy concern on…
…
continue reading
1
Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding
17:50
17:50
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
17:50
The availability of novel nonfactor therapeutics is revolutionizing the management of hemophilia in individuals with inhibitory antibodies, as well as making prophylaxis more convenient even in the absence of inhibitors. Unfortunately, the use of these products has been associated with thrombotic events that are not typically seen with factor repla…
…
continue reading
1
Concizumab: a novel anti-TFPI therapeutic for hemophilia
15:48
15:48
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
15:48
Amy Shapiro discusses the recent approval of concizumab for the treatment of patients with hemophilia. This novel subcutaneous homeostatic rebalancing agent has proven to be useful for the treatment of patients with hemophilia A and B, and we hope you find this talk to be useful to understand it.Blood Advances Talks による
…
continue reading
1
Naive T-cell depletion in stem cell transplantation
24:05
24:05
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
24:05
Allogeneic hematopoietic stem cell transplantation (HCT) is curative in many patients with advanced hematopoietic malignancies. Donor T cells not only facilitate engraftment and protect against opportunistic pathogens and residual disease, but can also cause graft-versus-host disease (GVHD), with significant morbidity and mortality.…
…
continue reading
1
The management of venous thromboembolism in hospitalized patients with COVID-19
15:10
15:10
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
15:10
The high incidence of thromboembolic disease, and in particular venous thromboembolism (VTE), has emerged as an important consideration in hospitalized and critically ill patients with coronavirus disease 2019 (COVID-19).Blood Advances Talks による
…
continue reading
1
Gene therapy for hemophilia: anticipating the unexpected
16:35
16:35
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
16:35
The treatment of hemophilia, which has undergone many transformative changes over the past 60 years, is poised for yet another disruptive change: the use of gene therapy to produce functional cures in some persons with hemophilia A or B.Blood Advances Talks による
…
continue reading
1
The changing landscape of anticoagulation in cancer-associated thrombosis
16:26
16:26
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
16:26
The changing landscape of anticoagulation in cancer-associated thrombosisBlood Advances Talks による
…
continue reading
1
TA-TMA: state of the art for diagnosis and treatment
19:30
19:30
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
19:30
Blood Advances Talks による
…
continue reading
1
Inherited predisposition to myeloid malignancies
18:39
18:39
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
18:39
Inherited predisposition to myeloid malignancies by Blood Advances TalksBlood Advances Talks による
…
continue reading
1
Managing patients who are receiving warfarin (or DOAC)and need an elective surgery or procedure
21:36
21:36
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
21:36
Managing patients who are receiving warfarin (or DOAC)and need an elective surgery or procedure by Blood Advances TalksBlood Advances Talks による
…
continue reading
1
Daily light-and-darkness onset regulates mouse hematopoietic stem cells
17:14
17:14
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
17:14
Daily light-and-darkness onset regulates mouse hematopoietic stem cells by Blood Advances TalksBlood Advances Talks による
…
continue reading
1
Extended therapy for unprovoked venous thromboembolism: when is it indicated?
16:16
16:16
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
16:16
Extended therapy for unprovoked venous thromboembolism: when is it indicated? by Blood Advances TalksBlood Advances Talks による
…
continue reading
1
Antiplatelet therapy in the management of atherothrombosis: recent clinical advances
16:21
16:21
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
16:21
Antiplatelet therapy in the management of atherothrombosis: recent clinical advances by Blood Advances TalksBlood Advances Talks による
…
continue reading
1
Challenges facing the benign hematology physician-scientist workforce
8:47
8:47
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
8:47
Challenges facing the benign hematology physician-scientist workforce by Blood Advances TalksBlood Advances Talks による
…
continue reading
1
Choosing for whom to recommend allogeneic transplantation for AML in CRL
17:58
17:58
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
17:58
Choosing for whom to recommend allogeneic transplantation for AML in CRL by Blood Advances TalksBlood Advances Talks による
…
continue reading
1
Catalyzing innovation in clinical trial design and analysis at NHLBI
15:25
15:25
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
15:25
Catalyzing innovation in clinical trial design and analysis at NHLBI by Blood Advances TalksBlood Advances Talks による
…
continue reading
1
ITP and thrombosis: an intriguing association
23:51
23:51
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
23:51
ITP and thrombosis: an intriguing association by Blood Advances TalksBlood Advances Talks による
…
continue reading
1
The current therapeutic landscape of FLT3 inhibitors
15:31
15:31
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
15:31
The current therapeutic landscape of FLT3 inhibitors by Blood Advances TalksBlood Advances Talks による
…
continue reading
1
How many mice? Design considerations for murine studies
16:22
16:22
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
16:22
How many mice? Design considerations for murine studies by Blood Advances TalksBlood Advances Talks による
…
continue reading
1
The Direct Oral Anticoagulants – can we finally stop using rat poison?
10:02
10:02
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
10:02
The Direct Oral Anticoagulants – can we finally stop using rat poison? by Blood Advances TalksBlood Advances Talks による
…
continue reading
1
Impact of the ICAL on the treatment of acute leukemia
22:42
22:42
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
22:42
Impact of the ICAL on the treatment of acute leukemia by Blood Advances TalksBlood Advances Talks による
…
continue reading
Venetoclax: a primer by Blood Advances TalksBlood Advances Talks による
…
continue reading
1
Technological Solutions For Global Hematology And Oncology
17:09
17:09
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
17:09
Technological Solutions For Global Hematology And Oncology by Blood Advances TalksBlood Advances Talks による
…
continue reading
1
The Lucky Iron Fish: a simple solution for iron deficiency
10:18
10:18
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
10:18
The Lucky Iron Fish: a simple solution for iron deficiency by Blood Advances TalksBlood Advances Talks による
…
continue reading
1
New developments in the management of sickle cell disease
12:29
12:29
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
12:29
New developments in the management of sickle cell disease by Blood Advances TalksBlood Advances Talks による
…
continue reading
Should we avoid heparin to eliminate HIT? by Blood Advances TalksBlood Advances Talks による
…
continue reading